U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493577) titled 'Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)' on March 10.
Brief Summary: An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Study Start Date: July 23, 2026
Study Type: INTERVENTIONAL
Condition:
Aneurysmal Subarachnoid Hemorrha...